Go Long [Term]: Amgen's M&A Playbook Offers Range of Deals
By Jennifer Boggs
Wednesday, May 4, 2011
SAN FRANCISCO Burrill & Co. reported last month that the past decade of merger and acquisition (M&A) activity by major pharmaceutical firms has failed to build value, suggesting that the drug development industry might be wasting its time on acquisitions.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.